Mads Hald Andersen

Mads Hald Andersen

Clinical Professor

Member of:

    ORCID: 0000-0002-2914-9605

    Publication year:
    All
    1 - 8 out of 8Page size: 10
    1. 2010
    2. Published

      Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial

      Trepiakas, R., Berntsen, A., Hadrup, S. R., Bjørn, J., Geertsen, P. F., Straten, P. T., Andersen, Mads Hald, Pedersen, Anders Elm, Soleimani, A., Lorentzen, T., Johansen, Julia Sidenius & Svane, Inge Marie, 1 Oct 2010, In: Cytotherapy. 12, 6, p. 721-34 14 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    3. Published

      The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens

      Straten, P. T., Andersen, Mads Hald & Andersen, Mads Hald, 1 Aug 2010, In: OncoTarget. 1, 4, p. 239-45 7 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      Therapeutic cancer vaccines in combination with conventional therapy

      Andersen, Mads Hald, Junker, N., Ellebaek, E., Svane, Inge Marie, Thor Straten, P. & Andersen, Mads Hald, 1 Jan 2010, In: Journal of Biomedicine and Biotechnology. 2010, p. 237623

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. Published

      Combined Treatment with Dendritic Cell Vaccine and Low-Dose Cyclophosphamide in Patients with Malignant Melanoma

      Engell-Noerregaard, L., Ellebaek, E., Buch-Hansen, T. Z., Nikolajsen, K., Straten, P. T., Andersen, Mads Hald, Svane, Inge Marie & Andersen, Mads Hald, 2010, In: Journal of Immunotherapy. 33, 8, p. 876-877 2 p.

      Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

    6. Published

      Dendritic Cells Transfected with mRNA for p53, Survivin and hTERT as Treatment for Patients With Malignant Melanoma or Breast Cancer-A Phase I Study

      Engell-Noerregaard, L., Hansen, T. H., Met, Ö., Andersen, Mads Hald, Svane, Inge Marie & Andersen, Mads Hald, 2010, In: Journal of Immunotherapy. 33, 8, p. 876 1 p.

      Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

    7. Published

      Spontaneous Cytotoxic T cell Reactivity Against IDO Exists in Cancer Patients and in Healthy Donors

      Sørensen, R. B., Straten, P. T., Andersen, Mads Hald & Andersen, Mads Hald, 2010, In: Journal of Immunotherapy. 33, 8, p. 910-911 2 p.

      Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

    8. Published

      Therapeutic Vaccination Targeting Indoleamine-2, 3 Dioxygenase (IDO) Using a IDO Derived Class I Restricted Peptide in Combination with Aldara and Montanide for Patients With Locally Advanced or Metastatic Non Small-Cell Lung Cancer. A First-in-man Phase I Trial

      Buch-Hansen, T. Z., Sørensen, R. B., Mellemgaard, A., Straten, P. T., Andersen, Mads Hald, Svane, Inge Marie & Andersen, Mads Hald, 2010, In: Journal of Immunotherapy. 33, 8, p. 919-920 2 p.

      Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

    9. Published

      Therapeutic cancer vaccines

      Larsen, S. K., Svane, Inge Marie, Straten, P. T. & Andersen, Mads Hald, 2010, In: Current Cancer Therapy Reviews. 6, 2, p. 163-174

      Research output: Contribution to journal › Journal article › Research › peer-review

    ID: 13571778